Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PvP001 Gastric Gluten-Degradation in Healthy Volunteers
NCT03594331Phase 1Terminated
- Sponsor
- Danielle Kim Turgeon
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of PvP001 in celiac disease (3 arms), sponsored by Danielle Kim Turgeon. Primary endpoints: Number of treatment emergent adverse events at 2 weeks, Percentage of treatment emergent adverse events at 2 weeks and 2 more. Started May 2018; status: terminated.
02
Drugs
PvP001
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03594331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594331.